Humana execs sell $38M in shares

Amy Baxter | | Health Exec | Policy & Regulations

Humana’s top executives offloaded a significant sum of shares in late December, shedding about 107,077 Humana shares worth $37.7 million, Louisville Business First reported.

The selloff comes at a time when Humana’s share prices have been soaring, closing at a new all-time high of $365.88 on Dec. 16. Higher company earnings are matched with a rosy outlook for corporate tax cuts. In fact, 15 of Humana’s highest share price closings fell in November and December.

Humana CEO Bruce Broussard sold 62,700 shares for roughly $21.7 million, according to public filings.

Humana’s share prices, along with other major healthcare insurers, jumped on the news that a handful of Affordable Care Act taxes could be eliminated.

See the full story below:

Humana CEO, other execs offload $38M in company shares

Amy Baxter
Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Related Content

Mangione now faces federal charges, death penalty in murder of UHC CEO
FDA issues Class I recall on counterfeit infusion pump batteries
FDA issues alert on PCNL sheath safety after patient death
DOJ sues CVS over unlawful opioid prescriptions and reimbursement
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders
Advancing AI for vascular surgery will require a commitment to data integrity

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.